Problem: India is chasing a $130 billion pharma ambition by 2030, yet records the highest OAI rate outside the US and 25 FDA Warning Letters. Despite the doer-checker model, errors recur and checks fail to catch them, leaving plants with six-month incident backlogs, delayed batch release and consuming a quarter of leadership’s time. Solution: Manufacturers must redesign work in six steps: streamline the BPR, right-size supervisory span, and anchor it in a span framework. In parallel, CFT-led templates, same-day evidence capture, and a common priority system shift plants from reactive firefighting to fact-based, first-time-right resolution. Benefits: Redesigning execution and verification reduces new incidents by 30%-50% and cuts closure timelines by a further 20%-40%, freeing operators to work accurately and supervisors to review thoroughly. By catching incidents early and closing them fast, plants shift from reactive compliance to sustained audit readiness.

Indian pharma plants face six-month incident backlogs and delayed batch releases. Discover how redesigning work could help India credibly reach its $130 billion pharma ambition by 2030.

Key Takeaways

The compliance spiral in pharma manufacturing

Download PDF

India’s pharma plants show an ~18% OAI rate and 25 Warning Letters in two years. Discover why more checks do not stop repeat errors.